Trial Profile
A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Lanopepden (Primary) ; Linezolid
- Indications Bacterial infections; Skin infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.